Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

In November, management reported positive results from the phase III ZENITH study, which evaluated the drug in patients with PAH Functional Class (FC) III or IV at high risk of mortality.

The first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein ... and reduce the risk of worsening clinical events in adults with PAH after a priority review. PAH is a life ...

This is the second late-stage study on Winrevair, which was stopped early. In November, management reported positive results from the phase III ZENITH study, which evaluated the drug in patients with ...

26 Sotatercept is an activin receptor type IIA-Fc fusion protein being tested in clinical trials as a first-in-class treatment for PAH. 27 It has been granted a Breakthrough Therapy Designation by ...